» Articles » PMID: 4570671

Double-blind Evaluation of Verapamil, Propranolol, and Isosorbide Dinitrate Against a Placebo in the Treatment of Angina Pectoris

Overview
Journal Br Med J
Specialty General Medicine
Date 1973 Feb 17
PMID 4570671
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

In the treatment of angina pectoris a double-blind evaluation of verapamil (Cordilox) at two dose levels-namely, 80 mg thrice daily and 120 mg thrice daily-propranolol (Inderal) 100 mg thrice daily, and isosorbide dinitrate (Vascardin) 20 mg thrice daily has been made against a placebo. The assessment was based on relief from daily attacks of angina on effort and the response to a whole-body exercise test. We can find no statistically significant difference between the effects of verapamil (120 mg three times a day) and propranolol (100 mg three times a day) in the treatment of angina of effort. Both of these preparations are more effective than a placebo both in the reduction of daily attacks (P < 0.01) and in the prolongation of exercise test (P < 0.05). Isosorbide dinitrate (20 mg three times a day) appears to be no more effective than a placebo in the treatment of angina on effort, but 14 out of 32 patients experienced headache of such severity that even when the dose was reduced to 10 mg thrice daily this drug therapy had to be withdrawn. Both propranolol (100 mg three times a day) and verapamil (120 mg three times a day) had a significant lowering effect on the diastolic blood pressure as measured with the patient standing (P < 0.01).

Citing Articles

Verapamil and Alzheimer's Disease: Past, Present, and Future.

Popovic N, Morales-Delgado N, Vidal Mena D, Alonso A, Pascual Martinez M, Caballero Bleda M Front Pharmacol. 2020; 11:562.

PMID: 32431612 PMC: 7214748. DOI: 10.3389/fphar.2020.00562.


Discovery and Development of Calcium Channel Blockers.

Godfraind T Front Pharmacol. 2017; 8:286.

PMID: 28611661 PMC: 5447095. DOI: 10.3389/fphar.2017.00286.


Calcium antagonists: A new class of therapeutic agents.

Gunawan A, Massumi A, Hall R Cardiovasc Dis. 1981; 8(3):413-420.

PMID: 15216199 PMC: 287966.


Differential effects of the calcium antagonist, verapamil, on lumen sizes of terminal arterioles and muscular venules in the rat mesenteric, pial and skeletal muscle microvasculatures.

Altura B, Altura B, Gebrewold A Br J Pharmacol. 1980; 70(3):351-3.

PMID: 7437647 PMC: 2044357. DOI: 10.1111/j.1476-5381.1980.tb08709.x.


Role of calcium antagonists in cardiovascular therapy.

Dargie H, Rowland E, Krikler D Br Heart J. 1981; 46(1):8-16.

PMID: 7023517 PMC: 482595. DOI: 10.1136/hrt.46.1.8.


References
1.
Bellet S, Muller O . The electrocardiogram during exercise. Its value in the diagnosis of angina pectoris. Circulation. 1965; 32(3):477-87. DOI: 10.1161/01.cir.32.3.477. View

2.
Banks T, SHUGOLL G . Confirmatory physical findings in angina pectoris. JAMA. 1967; 200(12):1031-5. View

3.
Ross G, Jorgensen C . Cardiovascular actions of iproveratril. J Pharmacol Exp Ther. 1967; 158(3):504-9. View

4.
MASTER A . The Master two-step test. Am Heart J. 1968; 75(6):809-37. DOI: 10.1016/0002-8703(68)90042-2. View

5.
Phear D . Verapamil in angina: a double-blind trial. Br Med J. 1968; 2(5607):740-1. PMC: 1991653. DOI: 10.1136/bmj.2.5607.740. View